The most suitable targeted drugs for EGFR19 exon mutation include gefitinib and ositinib. EGFR19 exon mutation belongs to the golden mutation among EGFR19 mutations, and it is also one of the more common mutations in lung cancer, and the most suitable targeted therapeutic drugs include first-generation gefitinib and third-generation ositinib, etc. Gefitinib epidermal growth factor receptor tyrosine kinase inhibitor can prolong the patient’s growth. Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor, which can prolong the survival cycle and improve the quality of life of patients, but after the emergence of drug resistance, it needs to be replaced by other drugs; ositinib is an oral kinase inhibitor, which can directly act on the tumor target, reduce the size of the tumor and inhibit the growth of the tumor, and the therapeutic effect has been improved relative to the first generation and the second generation.